Novogen subsidiary raises US$10m
Thursday, 04 December, 2003
Marshall Edwards, the US subsidiary of Novogen (ASX:NRT), has raised US$10.1 million through the exercise of expiring warrants by shareholders.
Marshall Edwards is listed on London's AIM exchange (AIM:MSH), and in late September the company announced plans to list on the US's Nasdaq exchange.
According to Alan Husband, group VP for research at Marshall Edwards and research director at Novogen, the funds will be used to further progress clinical development of Marshall Edward's anti-cancer drug phenoxodiol.
Phenoxodiol is in Phase II clinical trials in both Australia and the US for a number of different cancers including ovarian, prostate and cervical cancer. In addition to its own chemotherapeutic effects, the drug appears to sensitise tumour cells to the effects of other chemotherapeutic agents.
The share price of Novogen remained steady at AUD$8.00 in Australia.
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
